文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高危前列腺癌中等大分割放疗联合盆腔淋巴结照射与雄激素抑制的长期结果

Long-Term Results of Moderate Hypofractionation to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer.
PubMed 文献 · Pract Radiat Oncol · 2020-07-29

这项前瞻性I/II期研究报告了高危前列腺癌患者接受中等大分割放疗(60 Gy/20次,4周)同步整合推量照射前列腺、盆腔淋巴结接受44 Gy/20次,联合雄激素剥夺治疗(ADT)的长期结局。中位随访74个月,≥2级晚期胃肠道和泌尿生殖毒性分别为7%和9%,无4-5级毒性;5年和7年总生存率分别为91%和85%,无复发生存率分别为87%和81%。结论认为该方案可行、耐受良好且有效。

要点

  • 中等大分割放疗(60 Gy/20次)同步整合推量照射前列腺和盆腔淋巴结,联合ADT,晚期≥2级胃肠和泌尿毒性低。
  • 中位随访74个月,5年和7年总生存率分别为91%和85%,无复发生存率分别为87%和81%。
  • 无4-5级毒性,末次随访时≥2级胃肠和泌尿毒性分别为2%和3%,无残留≥3级毒性。

核心结论

  • 高危前列腺癌接受中等大分割放疗联合盆腔淋巴结照射和ADT是可行、耐受良好且有效的。

研究设计与样本

  • 前瞻性I/II期研究,纳入2010年10月至2014年2月治疗的105例局限性高危前列腺癌患者。

主要发现

  • 中位随访74个月,97%患者随访超过36个月,中位ADT duration为18个月。
  • ≥2级晚期胃肠道和泌尿生殖毒性分别见于7%和9%的患者,无4级或5级毒性。
  • 末次随访时≥2级胃肠道和泌尿生殖毒性分别为2%和3%,无残留≥3级毒性。
  • 5年和7年 actuarial 总生存率分别为91%和85%,无复发生存率分别为87%和81%。

关键数值与推荐

  • 放疗方案:前列腺60 Gy/20次(4周),盆腔淋巴结44 Gy/20次,同步整合推量技术,IMRT。
  • ADT在HypoRT开始前2至3个月启动,中位持续时间18个月。

临床怎么用

  • 对于高危前列腺癌,可考虑中等大分割放疗同步整合推量照射前列腺和盆腔淋巴结,联合ADT。
  • 该方案疗程短(4周),便于患者和医疗系统,但需更大规模随机试验验证。

局限性

  • 为I/II期研究,样本量105例,非随机对照,结论需更大随机试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Moderate hypofractionated radiation therapy (HypoRT) is an attractive alternative to conventionally fractionated radiation therapy for prostate cancer. However, most studies using HypoRT only included the prostate as the target volume. We report long-term outcomes of patients with high-risk prostate cancer treated with androgen deprivation therapy (ADT) and HypoRT to the prostate and nodal areas with a simultaneous integrated boost technique. METHODS AND MATERIALS: Patients with localized, high-risk prostate cancer entered a prospective phase I/II study with a HypoRT regimen of 60 Gy/20 fractions (4 weeks) to the prostate volume while the nodal areas received 44 Gy in the same 20 fractions delivered with intensity modulated radiation therapy with a simultaneous integrated boost technique. ADT started 2 to 3 months before HypoRT. Toxicity was prospectively assessed according to the Common Terminology Criteria for Adverse Events v3. Outcomes rates were calculated by the actuarial method of Kaplan-Meier from the date of last radiation treatment until date of event. RESULTS: We report on the first 105 patients treated between October 2010 and February 2014. Median follow-up was 74 months, with 97% of patients followed for more than 36 months. Median ADT duration was 18 months. The worst grade 2 or higher late gastrointestinal or genitourinary toxicity was seen in 7% and 9%, respectively. There was no grade 4 or 5 toxicity. At the last follow-up, the rates of grade ≥2 gastrointestinal or genitourinary toxicity were 2% and 3%, respectively, with no residual grade ≥3 toxicity. The 5- and 7-year actuarial overall survival and relapse free survival were 91% and 85% and 87% and 81%, respectively. CONCLUSIONS: The longest follow-up report of moderate HypoRT (plus ADT) to the prostate and pelvic nodes shows that this approach is feasible, well tolerated, and effective. It is convenient for patients and the health system. A larger randomized trial using this approach is warranted.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Faria S, Ruo R, Perna M, et al. Long-Term Results of Moderate Hypofractionation to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer. Pract Radiat Oncol. 2020. PMID: 32738465. doi:10.1016/j.prro.2020.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。